We scan new podcasts and send you the top 5 insights daily.
Manali reports Epco-R2's phase 3 follicular lymphoma trial showed a hazard ratio of 0.2 for PFS, but grade 3 or higher infections hit 33% and neutropenia 69%. MosinLen had less infection and is a time-limited doublet. If approved, the choice may trade triplet efficacy for better tolerability.
The phase 3 EPCOR FL-1 trial showed that adding epcoritamab to the lenalidomide/rituximab (R-squared) backbone profoundly improved progression-free survival in relapsed follicular lymphoma. Presented as the most important FL abstract at ASH, this result is expected to establish a new standard of care in this setting.
When choosing a bispecific antibody for follicular lymphoma, a major practical difference is the treatment duration. Mosunetuzumab is a time-limited therapy stopped after achieving a complete response, while Epcoritamab is given indefinitely until progression. This distinction heavily influences selection, especially for elderly patients.
A novel trial design used mosinutuzumab monotherapy first in frontline follicular lymphoma, adding lenalidomide only for patients without a complete response. This adaptive approach successfully spared about two-thirds of patients from the added toxicities of lenalidomide while still achieving very high overall efficacy.
When choosing between novel combinations in relapsed follicular lymphoma, a logical strategy is to use tafasitamab-lenalidomide-rituximab (Tafa-R2) first. After progression, single-agent epcoritamab remains highly effective. The reverse is not true, as tafasitamab monotherapy would not be effective after epcoritamab-R2 failure, making the initial choice critical.
Three-year data for odronextumab, given until progression in follicular lymphoma, reveals a high rate of severe (Grade 3+) infections (45%), including fatal events. This highlights a critical safety concern with continuous dosing and strengthens the clinical argument for using fixed-duration bispecific regimens to mitigate long-term toxicity.
Manali says Epco-R2 caused grade 3 or higher neutropenia in 69% of patients, so co-management with community partners often means dose-reducing or holding lenalidomide to keep epcoritamab going. This practical lever matters as the triplet enters second-line follicular lymphoma practice. It may prevent unnecessary epcoritamab discontinuation.
Data from the frontline AMPLIFY trial revealed that adding obinutuzumab to an acalabrutinib and venetoclax doublet doubled grade 3 or higher infections from 10-12% to 24%. While the triplet drove higher undetectable MRD rates, the heightened risk of neutropenia and severe infections argues against its use in older, comorbid patients.
Epcoritamab combined with lenalidomide and rituximab (EPCO R-squared) is now considered the preferred second-line regimen for most follicular lymphoma patients. It has demonstrated superior efficacy compared to the tafasitamab plus R-squared regimen, effectively 'knocking it off its perch' as the standard in this setting.
Data across multiple studies consistently shows that creating a triplet therapy by adding an antibody to an oral doublet significantly increases the risk of high-grade infections and cytopenias. This makes the two-drug oral combination a safer approach for managing Chronic Lymphocytic Leukemia (CLL).
Manali says that in rituximab-refractory follicular lymphoma she avoids chemotherapy such as bendamustine because a later CD19 CAR T option may be compromised by prior bendamustine. She would rather use Epco-R2 or MosinLen, preserving the CAR T path for patients who need it. She frames this as a key sequencing decision.